Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05398263 · ClinicalTrials.gov registry record · Phase 3
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT05398263 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 125 participants.
The verdict
NCT05398263, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05398263
The ClinicalTrials.gov registry entry for NCT05398263 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05398263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05398263 about?
NCT05398263 is a clinical study titled "Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma". A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
What is the current status of trial NCT05398263?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2022-08-09. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT05398263?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05398263?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.